Evidence map›Paper›PMID 18973238›Full record

ReviewMass spectrometry reviews

Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments.

Harald Mischak, Joshua J Coon, Jan Novak, Eva M Weissinger, Joost P Schanstra, Anna F Dominiczak

Abstract readReview
In one paragraph

Review in Mass spectrometry reviews. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Trial
  2. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides.Journal of the American Society of Nephrology : JASN · 2015
    Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Peptidomics and Capillary Electrophoresis.Advances in experimental medicine and biology · 2021
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Harald MischakMosaiques Diagnostics & Therapeutics, Hannover, Germany. mischak@mosaiques-diagnostics.com
Joshua J Coon
Jan Novak
Eva M Weissinger
Joost P Schanstra
Anna F Dominiczak

Funding

Immune Complexes and Mesangial Cells in IGA NephropathyP01DK061525 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MESTECKY, JIRI F · 2002 to 2006
$6.7M
Molecular Basis of Pathogenicity of IgA1-containing Immune ComplexesR01DK078244 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI JAN NOVAK · 2007 to 2026
$6.0M
Mucosal HIV and Immunobiology CenterR24DK064400 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SMITH, PHILLIP D · 2003 to 2012
$4.8M
Sequential Ion/Ion Reactions for Large Peptide and Whole Protein CharacterizationR01GM080148 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI COON, JOSHUA J · 2007 to 2015
$3.0M
IgA1 glycosylation and receptor interactions in IgA nephropathyR01DK071802 · NIDDK · UNIVERSITY OF CINCINNATI · PI HERR, ANDREW B · 2006 to 2010
$1.5M
IgA-secreting B cell lines: a novel tool for studies of IgA nephropathyR21DK080301 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NOVAK, JAN · 2008 to 2009
$399k
Molecular Basis of Pathogenicity of IgA1-containing Immune ComplexesR56DK078244 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI NOVAK, JAN · 2012 to 2012
$92k
British Heart Foundation BHF/RG/07/005/23633NIDDK NIH HHS DK061525NIDDK NIH HHS DK064400NIDDK NIH HHS DK071802NIDDK NIH HHS DK078244NIDDK NIH HHS DK080301NIDDK NIH HHS P01 DK061525NIDDK NIH HHS R01 DK071802NIDDK NIH HHS R01 DK078244NIDDK NIH HHS R21 DK080301NIDDK NIH HHS R24 DK064400NIDDK NIH HHS R56 DK078244NIGMS NIH HHS 1R01GM080148NIGMS NIH HHS R01 GM080148Wellcome TrustWellcome Trust 066780/2/012
6 · The paper itself

Abstract

Proteome analysis has emerged as a powerful technology to decipher biological processes. One of the main goals is to discover biomarkers for diseases from tissues and body fluids. However, the complexity and wide dynamic range of protein expression present an enormous challenge to separation technologies and mass spectrometry (MS). In this review, we examine the limitations of proteomics, and aim towards the definition of the current key prerequisites. We focus on capillary electrophoresis coupled to mass spectrometry (CE-MS), because this technique continues to show great promise. We discuss CE-MS from an application point of view, and evaluate its merits and vices for biomarker discovery and clinical applications. Finally, we present several examples on the use of CE-MS to determine urinary biomarkers and implications for disease diagnosis, prognosis, and therapy evaluation.

Indexed as

Electrophoresis, CapillaryMass SpectrometryBiomarkersDiagnostic Techniques and ProceduresHumansProteinsProteomeBiomarkersProteinsProteome

Identifiers

PMID18973238
PMCPMC2720435

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.